<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957436</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0160/1105 GETUG AFU-21</org_study_id>
    <nct_id>NCT01957436</nct_id>
  </id_info>
  <brief_title>A Phase III of ADT + Docetaxel +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-naïve Prostate Cancer.</brief_title>
  <acronym>PEACE1</acronym>
  <official_title>A PROSPECTIVE RANDOMISED PHASE III STUDY OF ANDROGEN DEPRIVATION THERAPY WITH DOCETAXEL WITH OR WITHOUT LOCAL RADIOTHERAPY WITH OR WITHOUT ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH METASTATIC HORMONE-NAÏVE PROSTATE CANCER.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center phase III study to compare the clinical benefit of androgen
      deprivation therapy (+ docetaxel) with or without local radiotherapy with or without
      abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients can be randomize in the trial after his consent form has been signed, and
      after all inclusion and non-inclusion criteria have been checked.

      The randomisation will result in the allocation of arm A (ADT +docetaxel), arm B (ADT
      +docetaxel +Abiraterone), arm C (ADT +docetaxel +radiotherapy) or arm D (ADT +docetaxel
      +Abiraterone +radiotherapy) in a 1:1:1:1 ratio.

      The randomization will be stratified (by minimization) according to:

        -  enrolment center,

        -  performance status (0 vs. 1-2)

        -  disease extent: lymph nodes only vs. bone (with or without lymph nodes) vs. presence of
           visceral metastases.

      CRPC is defined by cancer progression (either a confirmed PSA rise or a radiological
      progression) with serum testosterone being at castrated levels (&lt;0.50 ng/mL).

      When the CRPC stage is reached, castration (either LHRH agonist or LHRH antagonist) will be
      maintained in all patients.

      Investigators will be free to manage patients reaching CRPC at their discretion (using for
      example docetaxel, zoledronic acid, denosumab, sipuleucel-T, radium-223, cabazitaxel, etc)
      according to local uses and guidelines.

      Abiraterone may be used in arm A and C if abiraterone has become the standard treatment for
      CRPC when this stage is reached.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2013</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>5.5 years after the first inclusion</time_frame>
    <description>Overall and progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>8 months</time_frame>
    <description>The PSA response rate will be defined by an undetectable serum PSA level at 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective correlative study of PSA response/progression</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer specific survival</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain progression</measure>
    <time_frame>5.5 years</time_frame>
    <description>will be evaluated by questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next skeletal-related event</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to chemotherapy</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to severe local symptoms</measure>
    <time_frame>5.5 years</time_frame>
    <description>The time to severe local symptoms (grade 3 and 4 events) related to tumor progression and/or radiotherapy long term side effects will be evaluated according to NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>5.5 years</time_frame>
    <description>Toxicity (with a specific focus on the use of long-term low-dose steroids) will be evaluated according to NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The radiological progression-free survival</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of radiotherapy protocol on outcome</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1168</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>androgen deprivation therapy + docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A + radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B + radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abiraterone acetate</intervention_name>
    <description>abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)</description>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Androgen Deprivation Therapy</intervention_name>
    <description>The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>6 cycles at 75mg/m²/cycle, one cycle every 3 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the prostate,

          2. Metastatic disease documented by positive bone scan or CTscan or MRI. For patients
             with nodal metastases only, only patients with extra-pelvic enlarged lymph nodes can
             be included if they have either:

               -  At least one extra-pelvic lymph node ≥ 2 cm or

               -  extra-pelvic lymph node (s) ≥ 1 cm if the patients also have at least one pelvic
                  lymph node ≥ 2 cm

          3. Patients with ECOG ≤ 1 (PS 2 due to bone pain accepted),

          4. Life expectancy ≥ 6 months,

          5. Male aged ≥ 18 years old,

          6. Hemoglobin ≥ 10.0 g/dL,

          7. Platelet count ≥ 100,000/μL,

          8. Serum creatinine &lt; 1.5 x ULN or calculated creatinine clearance ≥ 60 mL/min,

          9. Serum potassium ≥ 4.0 mmol/L,

         10. Serum bilirubin ≤ 1.5 x ULN (except documented Gilbert's disease); AST and ALT ≤ 1.5 x
             ULN (≤ 5 ULN in case of liver metastases), ALP ≤ 2.5 x ULN

         11. Patients might have received a maximum of 3 months of ADT before randomization,

         12. Patients might have received previous radiation therapy directed to bone lesions

         13. Patients able to take oral medication,

         14. Patients who have received the information sheet and signed the informed consent form,

         15. Male patients who are receiving the study treatment and have partners of childbearing
             potential are advised to use a method of birth control with adequate barrier
             protection (condoms) as determined to be acceptable by the study doctor during the
             treatment period and for 4 weeks after the last dose of the study treatment.

         16. Patients must be willing and able to comply with scheduled visits, treatment plan,
             laboratory tests and other study procedures,

         17. Patients with a public or a private health insurance coverage,

         18. Patients willing to receive docetaxel

         19. Neutrophil ≥ 1500 cells/mm3

         20. Male patients who have partners of childbearing potential and/or pregnant partners are
             advised to use a method of birth control in addition to an adequate barrier protection
             (condoms) as determined to be acceptable by the study doctor during the treatment
             period and for 6 months after the last dose of docetaxel.

        Exclusion Criteria:

          1. Patients with previous local treatment directed to the prostate primary cancer. A
             previous TURP is allowed,

          2. Prior cytotoxic chemotherapy or biological therapy for the treatment of prostate
             cancer,

          3. Any chronic medical condition requiring a higher dose of corticosteroid than 5mg
             prednisone/prednisolone twice daily,

          4. Active infection or other medical condition for which corticosteroid use would be
             contraindicated,

          5. Previously treated with ketoconazole for prostate cancer for more than 7 days,

          6. Prior systemic treatment with an azole drug within 4 weeks of randomization,

          7. Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg),

          8. Patients with a history of hypertension except if blood pressure is controlled by
             anti-hypertensive treatment,

          9. Active or symptomatic viral hepatitis or chronic liver disease (except Gilbert's
             disease),

         10. History of pituitary or adrenal dysfunction,

         11. Small cell carcinoma of the prostate,

         12. Clinically known significant heart disease (myocardial infarction, arterial thrombotic
             events in the past 6 months, severe or unstable angina,NYHA Class II-IV heart disease
             or cardiac EF &lt; 50% at baseline,

         13. Atrial Fibrillation, or other cardiac arrhythmia requiring therapy,

         14. Other malignancy, except non-melanoma skin cancer, with a ≥ 30% probability of
             recurrence within 24 months,

         15. Known allergies, hypersensitivity or intolerance to the study drugs or excipients,

         16. Administration of an investigational therapeutic within 30 days of D1,

         17. Patients already included in another therapeutic trial involving an experimental drug,

         18. Patients with significantly altered mental status prohibiting the understanding of the
             study or with psychological, familial, sociological or geographical condition
             potentially hampering participation,

         19. Individual deprived of liberty or placed under the authority of a tutor.

        Additional criteria for patients receiving docetaxel:

        21. Patients with impaired vision should undergo a prompt and complete ophthalmologic
        examination. In case of Cystoid Macular Oeadema, the patient should not receive docetaxel.

        22. Concomitant use of strong CYP3A4 inhibitors ( clarithromycin, indinavir, nefazodone,
        nelfinavir, ritonavir, saquinavir, telithromycin) 23. Allergy to taxane
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim FIZAZI, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus Grand Paris - Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beata JUZYNA</last_name>
    <email>b-juzyna@unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soazig NENAN</last_name>
    <email>s-nenan@unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter SCHATTEMAN</last_name>
    </contact>
    <investigator>
      <last_name>Peter SCHATTEMAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Bordet Erasme- Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry GIL</last_name>
    </contact>
    <investigator>
      <last_name>Thierry GIL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Jolimont</name>
      <address>
        <city>Haine Saint Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick NEYBUCH</last_name>
    </contact>
    <investigator>
      <last_name>Yannick NEYBUCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk - Campus Vercruysselaan</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignace BILLIET</last_name>
    </contact>
    <investigator>
      <last_name>Ignace BILLIET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Louvain</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand TOMBAL</last_name>
    </contact>
    <investigator>
      <last_name>Bertrand TOMBAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Louvain</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand TOMBAL</last_name>
    </contact>
    <investigator>
      <last_name>Bertrand TOMBAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Radiotherapie Oncologie Moyenne Garonne-CROMG</name>
      <address>
        <city>Agen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier BERNARD</last_name>
      <phone>05 53 69 20 14</phone>
      <email>o.bernard@crmg-agen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre AUBERDIAC</last_name>
      <phone>+33(0)5 63 77 77 50</phone>
      <email>auberdiac@claude-bernard-albi.com</email>
    </contact>
    <investigator>
      <last_name>Pierre AUBERDIAC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de L'Europe</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de l'Ouest</name>
      <address>
        <city>ANGERS Cedex 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie ABADIE-LACOURTOISIE</last_name>
      <phone>+33(0)2 41 35 27 00</phone>
      <email>sophie.abadie-lacourtoisie@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie ABADIE-LACOURTOISIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Générale d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne DONEUX</last_name>
      <phone>+33(0)4 50 63 69 89</phone>
      <email>adoneux@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Anne DONEUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Marie Curie</name>
      <address>
        <city>Arras</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon Cedex 9</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lysian CARTIER</last_name>
      <phone>+33(0)4 90 27 68 44</phone>
      <email>l.cartier@isc84.org</email>
    </contact>
    <investigator>
      <last_name>Lysian CARTIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de la Baie</name>
      <address>
        <city>Avranches</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor-Emmanuel PERNIN</last_name>
      <phone>02 33 79 50 60</phone>
      <email>v.pernin@centredelabaie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie et de Radiothérapie du Pays Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien BLOUET</last_name>
      <phone>+33(0)5 59 59 38 71</phone>
      <email>aurelien.blouet@oncologie-pays-basque.org</email>
    </contact>
    <investigator>
      <last_name>Aurélien BLOUET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine THIERY-VUILLEMIN</last_name>
      <phone>+33(0)3 81 66 87 96</phone>
      <email>antoine.thieryvuillemin@oncologyfc2.onmicrosoft.com</email>
    </contact>
    <investigator>
      <last_name>Antoine THIERY-VUILLEMIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Pierre Curie</name>
      <address>
        <city>Beuvry</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie Fadin</last_name>
      <phone>03 21 61 92 70</phone>
      <email>afadin@radiopole-artois.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guilhem ROUBAUD</last_name>
      <phone>+33(0)5 56 33 33 33</phone>
      <email>g.roubaud@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Guilhem ROUBAUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali HASBINI</last_name>
      <phone>+33(0)2 98 31 32 00</phone>
      <email>alihasbini@oncologie-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Ali HASBINI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlon SILVA</last_name>
      <phone>02 31 45 50 50</phone>
      <email>m.silva@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Marlon SILVA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Alpes Leman</name>
      <address>
        <city>Contamine Sur Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol ALLIOT</last_name>
      <phone>+33(0)4 50 82 22 70</phone>
      <email>calliot@ch-alpes-leman.fr</email>
    </contact>
    <investigator>
      <last_name>Carol ALLIOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERA</name>
      <address>
        <city>Contamine Sur Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique LOISEAU</last_name>
      <phone>+33(0)6 60 63 56 28</phone>
      <email>domloiseau@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique LOISEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazid BELKACEMI</last_name>
      <phone>+33(0)1 49 81 45 22</phone>
      <email>yazid.belkacemi@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Yazid BELKACEMI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leonard de Vinci</name>
      <address>
        <city>Dechy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien CARLIER</last_name>
      <phone>03 27 08 60 61</phone>
      <email>dcarlier@clinique-psv.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François LECLERC</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne MARTIN</last_name>
      <phone>+33(0)3 80 73 75 18</phone>
      <email>emartin@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Etienne MARTIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Marguerite</name>
      <address>
        <city>Hyères</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François BERDAH</last_name>
      <phone>+33(0)4 94 12 55 60</phone>
      <email>jf.berdah@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-François BERDAH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La ROCHE sur YON</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank PRIOU</last_name>
      <phone>+33(0)2 51 44 61 73</phone>
      <email>frank.priou@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Frank PRIOU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric VOOG</last_name>
      <phone>+33(0)2 43 29 79 08</phone>
      <email>e.voog@cjb72.org</email>
    </contact>
    <investigator>
      <last_name>Eric VOOG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre CLAVERE</last_name>
      <phone>+33(0)5 55 05 62 68</phone>
      <email>pierre.clavere@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre CLAVERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude FLECHON</last_name>
      <phone>+33(0)4 78 78 26 43</phone>
      <email>aude.flechon@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Aude FLECHON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie TARTAS</last_name>
      <phone>04 78 86 43 18</phone>
      <email>'sophie.tartas@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Timone</name>
      <address>
        <city>MARSEILLE Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xavier MURACCIOLE</last_name>
      <phone>+33(0)4 91 38 43 34</phone>
      <email>xavier.muracciole@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>xavier MURACCIOLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenaëlle GRAVIS</last_name>
      <phone>+33(0)4 91 22 37 40</phone>
      <email>gravisg@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Gwenaëlle GRAVIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie BACIUCHKA-PALMARO</last_name>
      <phone>04 91 96 59 01</phone>
      <email>marjorie.baciuchka@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Intercommunal Le Raincy Montfermeil</name>
      <address>
        <city>Montfermeil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Basma M'BAREK</last_name>
      <phone>01 41 70 82 42</phone>
      <email>bmbarek@ch-montfermeil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Azuréen de Cancérologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe RONCHIN</last_name>
      <phone>+33(0)4 94 52 11 82</phone>
      <email>ronchinp@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe RONCHIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Radiothérapie de Macon</name>
      <address>
        <city>Mâcon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francois RENOULT</last_name>
      <phone>03 85 23 21 00</phone>
      <email>francois.renoult@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes Cedex 2</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude EL KOURI</last_name>
      <phone>+33(0)2 28 27 21 66</phone>
      <email>elkouri.claude@catherinedesienne.fr</email>
    </contact>
    <investigator>
      <last_name>Claude EL KOURI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Eve CHAND-FOUCHE</last_name>
      <phone>+33(0)4 92 03 12 70</phone>
      <email>marie-eve.chand@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Eve CHAND-FOUCHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Carémeau</name>
      <address>
        <city>NIMES Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane DROUPY</last_name>
      <phone>+33(0)4 66 68 33 51</phone>
      <email>stephane.droupy@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane DROUPY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Orléans la source</name>
      <address>
        <city>Orleans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise Champeaux-Orange</last_name>
      <phone>+33(0)2 38 51 47 78</phone>
      <email>elise.champeaux-orange@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Elise Champeaux-Orange</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BEUZEBOC</last_name>
      <phone>+33(0)1 44 32 46 80</phone>
      <email>philippe.beuzeboc@curie.net</email>
    </contact>
    <investigator>
      <last_name>Philippe BEUZEBOC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital St Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe HENNEQUIN</last_name>
      <phone>+33(0)1 42 49 90 24</phone>
      <email>christophe.hennequin@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe HENNEQUIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital TENON</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed KHALIL</last_name>
      <phone>01 56 01 60 51</phone>
      <email>ahmed.khalil@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chic Quimper</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike SCHLURMANN</last_name>
      <phone>+33(0)2 90 26 45 59</phone>
      <email>friederike.schlurmann@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Friederike SCHLURMANN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>RENNES Cedex</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte LAGUERRE</last_name>
      <phone>+33(0)2 99 25 31 82</phone>
      <email>b.laguerre@rennes.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte LAGUERRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Radiothérapie CROM et d'Oncologie Medical de L'Essonne</name>
      <address>
        <city>Ris-Orangis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian PFISTER</last_name>
      <phone>+33(0)2 32 88 81 63</phone>
      <email>christian.pfister@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Christian PFISTER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte VIE</last_name>
      <phone>+33(0)2 96 75 22 20</phone>
      <email>b.vie@clin-armoricaine.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte VIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU ST ETIENNE - Hôpital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <zip>44270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MOTTET-AUSELO</last_name>
      <phone>+33(0)4 77 82 83 31</phone>
      <email>nicolas.mottet@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas MOTTET-AUSELO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHP Saint Grégoire</name>
      <address>
        <city>Saint Gregoire</city>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier ARTIGNAN</last_name>
      <phone>+33(0)2 99 54 09 49</phone>
      <email>xartignan@vivalto-sante.com</email>
    </contact>
    <investigator>
      <last_name>Xavier ARTIGNAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie del'Ouest - site René Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane SUPIOT</last_name>
      <phone>+33(0)2 40 67 99 13</phone>
      <email>stephane.supiot@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane SUPIOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CENTRE DE CANCEROLOGIE Paris Nord</name>
      <address>
        <city>Sarcelles</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie GIROUX</last_name>
      <phone>01 39 90 49 55</phone>
      <email>drjuliegiroux@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>St PRIEST EN JAREZ</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy DE LAROCHE</last_name>
      <phone>+33(0)4 77 91 71 02</phone>
      <email>guy.delaroche@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Guy DE LAROCHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strasbourg Oncologie Libérale</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne ESCANDE</last_name>
      <phone>+33(0)3 88 45 37 50</phone>
      <email>aescande@neuf.fr</email>
    </contact>
    <investigator>
      <last_name>Anne ESCANDE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux du Leman</name>
      <address>
        <city>Thonon-les-bains</city>
        <zip>74203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Luc LANDRY</last_name>
      <phone>+33(0)4 50 83 23 67</phone>
      <email>j-landry@ch-hopitauxduleman.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Luc LANDRY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Toulon - La Seyne sur Mer - Hôpital Sainte Musse</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre GUILLET</last_name>
      <phone>+33(0)4 94 14 58 35</phone>
      <email>pierre.guillet@ch-toulon.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre GUILLET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>TOULOUSE Cedex 3</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor LATORZEFF</last_name>
      <phone>+33(0)5 67 20 44 00</phone>
      <email>i.latorzeff@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Igor LATORZEFF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>TOULOUSE Cedex</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc MOUREY</last_name>
      <phone>+33(0)5 61 42 41 20</phone>
      <email>mourey.loic@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Loïc MOUREY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de TOURS Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude LINASSIER</last_name>
      <phone>02 47 47 99 19</phone>
      <email>claude.linassier@univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie Saint Yves</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik MONPETIT</last_name>
      <phone>02 97 62 55 24</phone>
      <email>mylittle@centre-st-yves.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>INSTITUT GUSTAVE ROUSSY, Cancer Campus, Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Fizazi</last_name>
      <phone>+33(0)1 42 11 62 64</phone>
      <email>karim.fizazi@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Karim Fizazi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-klinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gesundheitszentrum Holzminden</name>
      <address>
        <city>Holzminden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul KELLY</last_name>
    </contact>
    <investigator>
      <last_name>Paul KELLY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adelaide and Meath incorporating National Children's hospital department</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mac DERMOTT</last_name>
    </contact>
    <investigator>
      <last_name>Mac DERMOTT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mac CAFFREY</last_name>
    </contact>
    <investigator>
      <last_name>Mac CAFFREY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mac CAFFREY</last_name>
    </contact>
    <investigator>
      <last_name>Mac CAFFREY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mac DERMOTT</last_name>
    </contact>
    <investigator>
      <last_name>Mac DERMOTT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DR SMALL</last_name>
    </contact>
    <investigator>
      <last_name>DR SMALL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Brescia - Sistema Socio Sanitaria Territoriale, ASST Spedali civili Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Gallà</last_name>
      <phone>0039 0543739954</phone>
      <email>valentina.galla@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Ugo De Giorgi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Camillo Forlanini Hospitals</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Maracchioni</last_name>
      <phone>0039 0658704356</phone>
      <email>maracchionifabio@gmail.it</email>
    </contact>
    <contact_backup>
      <last_name>Maria Lavinia Salvatori</last_name>
      <phone>0039 658704356</phone>
      <email>salvatorilavinia@yahoo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Cora Sternberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>'Hospital Bestriz angelo</name>
      <address>
        <city>Loures</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SANDRA Macedo</last_name>
      <phone>+351 96 3096 422</phone>
      <phone_ext>35168</phone_ext>
      <email>sandra.macedo@hbeatrizangelo.pt</email>
    </contact>
    <contact_backup>
      <last_name>Rita Cunha de Eça</last_name>
      <phone>+351 92 660 96 49</phone>
      <phone_ext>14075</phone_ext>
      <email>rheca@hospitaldaluz.pt</email>
    </contact_backup>
    <investigator>
      <last_name>Fabio Lopez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>'Instituto Portugues de Oncologia do Porto Francisco Gentil, E,P,E</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juliana Ferreira</last_name>
      <phone>+351 96 176 09 92</phone>
      <email>juliana@ipoporto.min-saude.pt</email>
    </contact>
    <contact_backup>
      <last_name>Márcia Correia</last_name>
      <phone>+351 96 176 09 92</phone>
      <email>marcia.correia@ipoporto.min-saude.pt</email>
    </contact_backup>
    <investigator>
      <last_name>Nuno SOUSA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sc Radiotherapy Center Cluj SRL</name>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel KACSO</last_name>
    </contact>
    <investigator>
      <last_name>Gabriel KACSO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador VILLA FREIXA</last_name>
      <phone>+34934978805</phone>
      <email>svilla@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Salvador VILLA FREIXA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital De la Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma SANCHO</last_name>
      <phone>+34 935537756</phone>
      <email>gsancho@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Gemma SANCHO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejo RODRIGUES-VIDA</last_name>
      <phone>+34 9324 83 137</phone>
      <email>arodriguezvida@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Alejo RODRIGUES-VIDA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier MALDONADO</last_name>
      <phone>+34 93 2746125</phone>
      <email>xmaldonado@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Xavier MALDONADO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Girona - Hospital Josep Trueta</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvar ROSELLO</last_name>
      <phone>+34 972 22 58 34</phone>
      <email>nsgonzalez@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Alvar ROSELLO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital 12 OCTUBRE</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus GARCIA DONAS</last_name>
      <phone>+34 91 732 8000</phone>
      <email>jgarciadonas@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Jesus GARCIA DONAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Althaia</name>
      <address>
        <city>Manresa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>'Hospital Clinico Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Correa</last_name>
      <phone>34951032617</phone>
      <email>racoge@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Raquel Correa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>'Parc Tauli Sabadell Hospital Universitari</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Gomez VEIGA</last_name>
      <phone>34669848799</phone>
      <email>fgveiga@telefonia.net</email>
    </contact>
    <investigator>
      <last_name>Francisco Gomez VEIGA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondation Dr. Henri Dubois-Ferrière Dinu Lipatti</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie Ancrenaz-Sirot</last_name>
      <phone>+41 79 55 32 381</phone>
      <email>virginie.ancrenaz@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Anna PATRIKIDOU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole JAMES FARESSE</last_name>
      <phone>+41 (0)21 314 3369</phone>
      <email>Nicole.James-Faresse@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Bérangère Medez</last_name>
      <phone>+41 (0)21 314 3370</phone>
      <email>Berangere.midez@chuv.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Dominik Berthold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>metastatic hormone-naive</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>abiraterone acetate</keyword>
  <keyword>docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

